Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in CDKL5 Deficiency Disorder
NCT05249556Phase 3Not yet recruiting
- Sponsor
- Immedica
- Start
- Mar 2027
- Primary completion
- Dec 2029
- Modality
- Allosteric Modulators
01
Overview
Phase 3, open-label, single-arm trial of ganaxolone in CDKL5 deficiency disorder (CDD), sponsored by Immedica. Primary endpoints: Ganaxolone exposure at 17 weeks and Safety and tolerability of ganaxolone at 52 weeks. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NCT05249556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249556.